Core Viewpoint - Huaborn Neutron Technology Co., Ltd. has completed a multi-hundred million RMB Pre-A round financing, indicating strong market confidence in Boron Neutron Capture Therapy (BNCT) as a promising treatment method [2][11]. Company Overview - Established in 2023 and headquartered in Hangzhou, Zhejiang, Huaborn Neutron is a national high-tech enterprise focused on the research, production, and application of accelerator-driven BNCT technology [3]. - The company was founded by Wang Sheng, a renowned neutron scientist, and has assembled a team of experts across various disciplines including nuclear physics, software, control, mechanics, pharmacy, clinical medicine, and materials science [3]. Main Products and Technologies - Huaborn Neutron has developed the HyBorSys® BNCT full-process solution, which includes an accelerator neutron source system, boron drugs, and a treatment planning system (TPS), achieving a complete closed-loop for BNCT technology [4]. - The BNCT equipment utilizes a high-current proton RFQ accelerator and long-life solid lithium target technology, ensuring high power stability and a target lifespan that is globally leading (>1500 mA·h) [6]. - The company has established a research and development system for boron drug synthesis, significantly improving product quality and reducing production costs [7]. - The domestically developed TPS can model based on multi-modal imaging data from patients, simulating dose distribution using Monte Carlo particle transport programs for precise prediction and individualized treatment planning [9]. Current Status and Future Prospects - The HyBorSys® demonstration device has completed medical device registration inspection, and the boron drug is about to enter the IND application stage [10]. - BNCT is recognized as a significant breakthrough in the field of radiotherapy, gradually moving towards clinical application, with Huaborn Neutron achieving independent breakthroughs in devices, drugs, and software within two years [11]. - The recent financing round, attracting several hundred million RMB, reflects the capital market's high recognition of BNCT as a cutting-edge therapy [11].